5 Einträge gefunden

1. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

   1. Untch, Michael
   2. Fasching, Peter A
   3. Konecny, Gottfried E
   4. Hasmüller, Stephan
   5. Lebeau, Annette
   6. Kreienberg, Rolf
   7. Camara, Oumar

   2011 - Forschungsinformationssystem des UKE
2. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

   1. Untch, Michael
   2. Muscholl, Michael
   3. Tjulandin, Sergei
   4. Jonat, Walter
   5. Meerpohl, Hans-Gerd
   6. Lichinitser, Mikhail
   7. Manikhas, Alexey G

   2010 - Forschungsinformationssystem des UKE
3. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

   1. Harter, Philipp
   2. Hilpert, Felix
   3. Mahner, Sven
   4. Heitz, Florian
   5. Pfisterer, Jacobus
   6. Andreas, Du Bois

   2010 - Forschungsinformationssystem des UKE
4. Role of cytoreductive surgery in recurrent ovarian cancer.

   1. Harter, Philipp
   2. Hilpert, Felix
   3. Mahner, Sven
   4. Kommoss, Stefan
   5. Heitz, Florian
   6. Andreas, Du Bois

   2009 - Forschungsinformationssystem des UKE
5. Prognostic factors for complete debulking in first- and second-line ovarian cancer.

   1. Harter, Philipp
   2. Hilpert, Felix
   3. Mahner, Sven
   4. Kommoss, Stefan
   5. Heitz, Florian
   6. Pfisterer, Jacobus
   7. Andreas, Du Bois

   2009 - Forschungsinformationssystem des UKE